Citation only
via Europe PMC
The Burden of Alzheimer's Disease and Other Dementias Attribute to Metabolic Risks in Western Europe From 1990 to 2023.
Hao N, Zhang X, He Z, Zhang J, Li X, Zhao G, Fang J, Chen W.
Diabetes, obesity & metabolism · 2026
Abstract
<h4>Background</h4>Alzheimer's disease and other dementias (ADOD) impose a growing burden in aging high-SDI regions, a composite of income, education, and fertility. Metabolic risks are major modifiable contributors, but region-specific estimates for Western Europe are limited.<h4>Methods</h4>Using GBD 2023 data, we estimated deaths, disability-adjusted life years (DALYs), age-standardized mortality rates (ASMR), and age-standardized DALYs rates (ASDR) attributable to metabolic risks in 24 countries. Analyses were stratified by sex, age, and Level 2 metabolic risks (high BMI, high FPG). Temporal trends were assessed using estimated annual percentage change (EAPC), and decomposition analysis quantified contributions from population growth, aging, and epidemiological change.<h4>Results</h4>In 2023, ASMR and ASDR were 6.84 (95% UI: 1.38-18.30) and 117.80 (35.67-252.14) per 100 000, increasing 18.8% and 17.6% from 1990; corresponding EAPCs were 0.45 and 0.43. Metabolic risks accounted for 90094.8 deaths (18262.6-241493.9). Females had higher age-standardized rates; males showed slightly higher EAPCs. High FPG remained dominant, while high BMI increased faster, particularly among males. Monaco had the highest ASMR and ASDR, whereas Germany, Italy, and the United Kingdom contributed the largest absolute burden. Decomposition analysis showed demographic changes primarily drove high FPG burden, while epidemiological changes contributed more to high BMI outcomes.<h4>Conclusions</h4>ADOD burden attributable to metabolic risks continues to rise across Western Europe, with substantial variation across countries, sex, age, and risk factors. High FPG burden is largely demographic-driven; high BMI burden reflects adverse epidemiological trends. Findings support targeted metabolic interventions, including obesity control and diabetes management integrated into dementia prevention strategies.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- Europe PMC
- DOI
- 10.1111/dom.70978
- Canonical
- link ↗
- Fetched
- 2026-07-02 MST
Cite this
APA
N, H., X, Z., Z, H., J, Z., X, L., G, Z., J, F., & W., C. (2026). The Burden of Alzheimer's Disease and Other Dementias Attribute to Metabolic Risks in Western Europe From 1990 to 2023. <em>Diabetes, obesity & metabolism</em>. https://doi.org/10.1111/dom.70978
Vancouver
N H, X Z, Z H, J Z, X L, G Z, et al. The Burden of Alzheimer's Disease and Other Dementias Attribute to Metabolic Risks in Western Europe From 1990 to 2023. Diabetes, obesity & metabolism. 2026. doi:10.1111/dom.70978.
BibTeX
@article{hao2026TheBur,
title = {The Burden of Alzheimer's Disease and Other Dementias Attribute to Metabolic Risks in Western Europe From 1990 to 2023.},
author = {Hao N and Zhang X and He Z and Zhang J and Li X and Zhao G and Fang J and Chen W.},
journal = {Diabetes, obesity & metabolism},
year = {2026},
doi = {10.1111/dom.70978},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Diabetes research and clinical practice 2026
Citation only
Global burden of chronic kidney disease due to type 2 diabetes in adults from 1990 to 2021, with exploratory projections to 2036: a systematic analysis of the Global Burden of Disease Study 2021.
Frontiers in Public Health 2025
Open access · CC-BY
The current status, trends, and challenges of Alzheimer’s disease and other dementias in Asia (1990–2036)
Cell chemical biology 2024
Preprint · OA
β-hydroxybutyrate is a metabolic regulator of proteostasis in the aged and Alzheimer disease brain
Scientific Reports 2016
Open access · CC-BY
Energy crisis precedes global metabolic failure in a novel Caenorhabditis elegans Alzheimer Disease model
Menopause (New York, N.Y.) 2026
Citation only
Regional disparities and metabolic determinants of type 2 diabetes in women aged 55 and older.
The Lancet Healthy Longevity 2024
Open access · CC-BY